Navigation Links
Mainz University obtains new CRC 'Nanodimensional polymer therapeutics for tumor therapy'
Date:5/31/2013

The German Research Foundation (DFG) has established a new Collaborative Research Center on "Nanodimensional polymer therapeutics for tumor therapy" (CRC 1066) at Johannes Gutenberg University Mainz (JGU) and the Max Planck Institute for Polymer Research (MPI-P). Starting in October 2013, the Collaborative Research Center will receive grants totaling approximately EUR 11 million over four years to develop a nanoparticle-based cancer therapy to combat melanoma as an immunogenic tumor model. The Mainz scientists will focus on a form of cancer immunotherapy that is specifically suitable for permanently eliminating minimal residual disease, such as hidden metastases. The new CRC is notable for its interdisciplinary approach: chemists will study the synthetic feasibility and the structure-property relationships of carrier materials, while immunologists and biomedical specialists develop models for the optimal use of such carriers in the form of a new combination therapy for activating the body's immune response against the cancer. The coordinator of the new DFG-funded Collaborative Research Center is Professor Rudolf Zentel from the Institute of Organic Chemistry at Johannes Gutenberg University Mainz. Assistant coordinators are Professor Stephan Grabbe from the Department of Dermatology at the Mainz University Medical Center and Professor Katharina Landfester from the Max Planck Institute for Polymer Research in Mainz. In addition, the Board of Directors will include Professor Detlef Schuppan from the Department of Internal Medicine I at the Mainz University Medical Center and Dr. Mathias Barz from the JGU Institute of Organic Chemistry as a representative of young researchers.

The combination of the expertise of Johannes Gutenberg University Mainz and the Max Planck Institute for Polymer Research, one of the leading sites for polymer chemistry in Germany, together with the excellent research structure in the area of tumor immunotherapy at the Mainz Unive
'/>"/>

Contact: Professor Rudolf Zentel
zentel@uni-mainz.de
49-613-139-20361
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Launch of Chinese-German Center for Bio-Inspired Materials at Mainz University Medical Center
2. Mainz University Medical Center receives further DFG funding for cardiovascular research
3. DFG funds new Collaborative Research Center at the Mainz University Medical Center
4. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
5. Scientists at the Mainz University Medical Center gain new insights into Taspase1 function
6. NY Times Bestselling Author Dr. Eben Alexander to Speak at Sofia University
7. NIKE Softball Camps Is Pleased To Announce the 2013 NIKE Softball ID Camp at Seattle University
8. Queens University receives Bill and Melinda Gates Foundation grants
9. 1-2-3 Magic, by ParentMagic, Given 5 Stars, Highly Recommend Rating by Experts in “Self-Help That Works” by Oxford University Press
10. Schimenti and Boston University Take A Second Look at Construction Cameras
11. University of New England Graduates First Class with Pharmacy Doctoral Degrees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... St. Louis, MO (PRWEB) , ... August 04, ... ... news, attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report ... documents.* Talcum powder lawyers provide regular news updates and cancer warning ...
(Date:8/4/2015)... ... 2015 , ... Please join us for the 4th Annual Doris A. ... Shores Park in Brewerton, NY. , Doris Connor was a healthy, active, Registered ... age of 59. Her family and friends have since become steadfast in their efforts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mr Didier Cauchois, ... impressive so far". , Mr Cauchois attributes the success to the dedication ... Dicma and the healthcare technology offered by Winscribe's platform. , "We have ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... partnership to make the Isabel Symptom Checker available to all users of the ... mechanism to check their symptoms in an easy, intuitive method, provides access to ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3
... Eastern Time Today -, IRVINE, Calif., March 13 ... in intravascular patient temperature,management therapies, today reported on its ... year ended December 31, 2007., Revenue for the ... to $2.0 million in the fourth quarter of 2006. ...
... In many areas of the modern world, molecules play ... Taxol is used to combat cancer, and aspirin is ... worldwide. MOLECULES THAT CHANGED THE WORLD (Wiley-Blackwell; March 2008; ... comprehensive guide to not only the synthesis of, but ...
... The following is a,statement by Lois Aronstein, AARP ... including a $400 million Housing,Opportunity Fund to improve the ... be used to provide needed opportunities,for low- and moderate-income ... The program will be administered by the State of ...
... to Expand Brand Awareness with the Strategic Placement, ... Event. Six Members of, this Year,s Field utilize ... RIDGE, N.J., March 13 Millennium,Biotechnologies Inc., wholly-owned ... MBTG) announced today that many PGA,players and spectators ...
... March 13 HHS, Agency for,Healthcare Research and ... health,information technology contracts that will focus on the ... clinical,decision support. Clinical decision support helps health professionals ... Women,s Hospital in Boston and Yale University School,of ...
... showed significant improvement in social functioning , , THURSDAY, ... 30 minutes of exercise a day can improve the ... American researchers suggest. , The analysis studied hundreds ... the Dose Response to Exercise in postmenopausal Women (DREW) ...
Cached Medicine News:Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 2Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 3Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 4Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 5Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 6Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 7Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 8Health News:Molecules that changed the world 2Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 2Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 3Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 4Health News:AHRQ Awards $5 Million to Help Integrate Clinical Decision Support Technologies Into Health Care Delivery 2Health News:Minimal Exercise Benefits Overweight Postmenopausal Women 2
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
(Date:8/3/2015)... Biosensors International Group, Ltd. ("Biosensors" or ... B20), a developer, manufacturer and marketer of innovative ... first fiscal quarter ended 30 June 2015 ("Q1 ... Developments: , Biosensors continued to ... driven by lower operating expenses and operational improvement. ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Array BioPharma Inc. ... the fourth quarter and full year of its ... Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib ... 3, are on track for regulatory submissions in ... BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ... investor update conference call for late November.  The purpose ... update on (i) the status of the Company,s efforts ... wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), ...
... 24, 2011 Neuralstem, Inc. (NYSE Amex: CUR ... trial of the company,s spinal cord stem cells in the ... at Emory University in Atlanta, Georgia. The company announced that, ... Food and Drug Administration (FDA) has granted approval for the ...
Cached Medicine Technology:Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 2Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 3Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 4
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: